D ilated nonischemic cardiomyopathy (DCM) is the most common indication for heart transplantation (1). DCM is characterized by systolic dysfunction and enlargement of 1 or both ventricles. The causes of DCM vary widely and include idiopathic, genetic, pregnancy, toxin, infectious, metabolic/endocrine, inflammatory/infiltrative/autoimmune, and neuromuscular disease mechanisms (2). There are additional mechanisms that can lead to cardiomyopathy which overlap phenotypically with DCM, including ischemic cardiomyopathy, hypertensive heart disease, and athlete's heart. The wide-ranging phenotypic overlap and diverse mechanisms which can result in DCM make the management challenging, especially with respect to predicting which individual patients will undergo left ventricular reverse remodeling (LVRR) in response to therapy. Although treatment includes removing the stressor, such as discontinuing alcohol for alcoholic DCM patients or starting methimazole for thyrotoxicosis, standard guideline-directed medical treatment (GDMT) also requires beta-blocker and renin-angiotensin-aldosterone system inhibitor therapy to promote reverse remodeling and recovery of systolic function. Unfortunately, despite our best efforts, many DCM patients do not recover cardiac function and subsequently progress to end-stage heart failure requiring advanced heart failure therapies (3). Evaluation for DCM often begins upon incidentally finding cardiomegaly on chest radiography; and typically, a careful history, physical examination, and echocardiography study yields clues to the cause. Additional work-up often requires cardiac magnetic resonance to evaluate for late gadolinium enhancement and, in many cases, an endomyocardial biopsy for histological analysis. Prior animal studies performed by Ko et al. (4) in this issue of JACC: Basic to Translational Science demonstrated that unrepaired DNA damage increases expression of inflammatory and DNA damage response signaling that play a causative role in the pathogenesis of heart failure (5). Ko et al. (4) hypothesized that DNA damage in DCM patients can be assessed from endomyocardial biopsy results and that these markers of DNA damage may be useful in predicting LVRR in response to GDMT. Specifically, the study evaluated 2 major markers of DNA damage, poly (ADP-ribose) (PAR) and g-H2A.X, by using immunohistochemical analysis of endomyocardial samples from 58 DCM patients prior to initiating 12 months of optimal GDMT. A total of 43% of these patients demonstrated LVRR, defined in the study as an absolute increase in LV ejection fraction $10% to a final value of >35% with a concomitant decrease in LV end-diastolic diameter $10%, whereas 57% of patients did not have LVRR in response to GDMT (i.e., they were LVRR-negative). PAR and g-H2A.X nuclear staining was significantly reduced in LVRR-positive patients, and propensity score analysis demonstrated that the proportions of PAR (%PAR) and %g-H2A.X staining
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